How Do PPIs Affect Patients with Bleeding Ulcers?

Shaughnessy, Allen F.
August 2005
American Family Physician;8/15/2005, Vol. 72 Issue 4, p683
Academic Journal
Presents the results of a case study regarding the effectiveness of proton pump inhibitor (PPI) on patients with bleeding peptic ulcers. Factor which enhances platelet function and inhibit fibrolysis in patients with an acute bleeding peptic ulcer; Effect of PPI treatment on mortality rates among patients with the disease; Comparison of outcomes in patients who underwent oral treatment with intravenous treatment.


Related Articles

  • Effects of Proton Pump Inhibitors on Platelet Function in Patients Receiving Clopidogrel: A Systematic Review. Kwok, Chun Shing; Loke, Yoon Kong // Drug Safety;2012, Vol. 35 Issue 2, p127 

    Background: There is considerable debate regarding the negative impact of concomitant proton pump inhibitor (PPI) therapy on the antiplatelet efficacy of clopidogrel. Aim: The aim of this study was to perform a systematic review of studies that have evaluated the platelet function of patients...

  • Use of acid-suppression therapy for treatment of non-variceal upper gastrointestinal bleeding. Olsen, Keith M. // American Journal of Health-System Pharmacy;5/15/2005 Supplement 2, Vol. 62, pS18 

    Purpose. Prognostic factors in patients with peptic ulcer bleeding and therapeutic strategies for preventing the recurrence of bleeding are described. Summary. The risk of complications and death in a patient with acute upper gastrointestinal bleeding can be predicted based on certain clinical...

  • PPI treatment beneficial to patients with ulcer bleeding, according to meta-analysis.  // Formulary;Jun2007, Vol. 42 Issue 6, p391 

    The article focuses on the study that examines the benefits of proton-pump inhibitors (PPIs) for patients with ulcer bleeding. According to the study, the use of PPIs for ulcer bleeding effectively reduces the risk of bleeding and the need for surgical intervention and repeated endoscopic...

  • Proton Pump Inhibitors After Endoscopic Hemostasis in Patients With Peptic Ulcer Bleeding. Mesihovic, Rusmir; Vanis, Nenad; Mehmedovic, Amila; Gornjakovic, Srdjan; Gribajcevic, Mehmed // Medicinski Arhiv;2009, Vol. 63 Issue 6, p323 

    Background: Peptic ulcer bleeding is a common and potentially fatal condition. For patients with bleeding peptic ulcers that display major endoscopic stigmata of recent hemorrhage, a combination of endoscopic and pharmacologic therapy is the current standard management. Objective: To show our...

  • Continuous Infusion of Pantoprazole versus Ranitidine for Prevention of Ulcer Rebleeding: A U.S. Multicenter Randomized, Double-Blind Study. Jensen, Dennis M.; Pace, Samuel C.; Soffer, Elaine; Comer, Gail M. // American Journal of Gastroenterology;Sep2006, Vol. 101 Issue 9, p1991 

    OBJECTIVES: No North American randomized study has compared ulcer rebleeding rates after endoscopic hemostasis in high-risk patients treated with high-dose intravenous (IV) proton pump inhibitors (PPIs) or IV histamine-2 receptor antagonists. Our hypothesis was that ulcer rebleeding with IV...

  • Proton pump inhibitors for acid suppression in the intensive care unit: Formulary considerations. Devlin, John W. // American Journal of Health-System Pharmacy;5/15/2005 Supplement 2, Vol. 62, pS24 

    Purpose. The rationale for limiting the proton pump inhibitor (PPI) products included in an institutional formulary, factors to consider when making formulary decisions about PPI products, the results and limitations of cost-effectiveness analyses of PPI therapy in critically ill patients, the...

  • Proton pump inhibitors (PPIs)--too much of a good thing? Bryant, Linda // Journal of Primary Health Care;Mar2012, Vol. 4 Issue 1, p72 

    The article offers information on proton pump inhibitors (PPIs). Prescribed classes of medicines under the PPI category include omeprazole, pantoprazole and lansoprazole. Their indication include gastro-oesophageal reflux disease (GORD) and peptic ulcer disease. Common, less common and rare side...

  • Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors. Craig, D.G.N.; Thimappa, R.; Anand, V.; Sebastian, S. // QJM: An International Journal of Medicine;May2010, Vol. 103 Issue 5, p327 

    Background: Intravenous (IV) proton pump inhibitors (PPI) reduce rebleeding from high-risk peptic ulcers following endoscopic therapy. The majority of IV PPI prescriptions in US hospital practice are inappropriate, leading to unnecessary drug costs, drug shortages and potential adverse events....

  • Intravenous Lansoprazole: A Viewpoint by Neville Yeomans. Yeomans, Neville // Drugs;2004, Vol. 64 Issue 18, p2090 

    The intravenous proton pump inhibitor, lansoprazole, is useful for patients who cannot take oral preparations. It is also used for obtaining rapid control of gastric activity in high-risk patients with bleeding peptic ulcers. Studies have shown that intravenous lansoprazole has similar to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics